BiotechTube

9-valent HPV vaccination

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anal Intraepithelial Neoplasia

Conditions

Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus

Trial Timeline

Sep 1, 2022 → May 1, 2026

NCT ID
NCT03947775

About 9-valent HPV vaccination

9-valent HPV vaccination is a phase 2 stage product being developed by Merck for Anal Intraepithelial Neoplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03947775. Target conditions include Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03947775Phase 2Recruiting

Competing Products

20 competing products in Anal Intraepithelial Neoplasia

See all competitors
ProductCompanyStageHype Score
aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxibJohnson & JohnsonApproved
85
AcetaminophenJohnson & JohnsonPhase 2
52
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
85
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
52
Vandetanib + Capecitabine + Oxaliplatin + BevacizumabAstraZenecaPhase 1
33
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Cetuximab + Mitomycin C + 5-FluoruracilMerckPhase 1
33
Pembrolizumab + Paclitaxel + Carboplatin + PembrolizumabMerckPhase 2
52
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccineMerckPhase 2
52
GardasilMerckPre-clinical
23
Sample collectionNovartisPhase 2
52
Atezolizumab plus TiraglolumabRochePhase 2
52
MPDL3280A + mDCFRochePhase 2
52
panitumumab, mytomicin C, 5-FU, radiationAmgenPhase 2
51
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
32
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
76

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85